Dual-Pathway Medical Weight Loss: How Two-Receptor Therapy Works

What dual-pathway therapy is

Dual-pathway weekly injectables activate both the primary gut incretin receptor and the GIP receptor. The first pathway reduces appetite and slows gastric emptying; GIP is a second incretin hormone that appears to improve insulin sensitivity and how the body handles fat. Hitting two pathways instead of one is the structural reason dual-pathway therapy behaves differently from single-pathway drugs.

How it compares on weight loss

In its pivotal obesity trial (SURMOUNT-1), dual-pathway therapy produced up to about 21% mean body-weight reduction at the 15 mg dose over 72 weeks. In a head-to-head trial against single-pathway therapy (SURMOUNT-5), the dual-pathway injectable produced more weight loss (roughly 20% versus 14% mean), with a larger share of participants reaching the 15% and 20% thresholds. On current evidence it is the more powerful weight-loss approach on average, though "on average" matters: the right medication for any individual depends on labs, budget, and tolerance. See our full dual-pathway vs single-pathway comparison.

Dual-pathway dosing chart

Dual-pathway therapy is a once-weekly subcutaneous injection that steps up roughly every 4 weeks. The standard titration is:

• Weeks 1-4: 2.5 mg once weekly (starting dose, not therapeutic)
• Weeks 5-8: 5 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10 mg once weekly
• Weeks 17-20: 12.5 mg once weekly
• Week 21 onward: 15 mg once weekly (maximum maintenance)

Maintenance is commonly 5, 10, or 15 mg depending on response and tolerance. Not everyone needs to reach 15 mg. The goal is the lowest dose that delivers steady progress without intolerable side effects, and your provider will hold or slow the schedule if needed.

Side effects

The side-effect profile is broadly similar to single-pathway weekly injectables because both slow the gut: nausea, constipation, diarrhea, and reflux, worst in the weeks after a dose increase and usually improving with time. Gallbladder issues and pancreatitis are uncommon but real (report severe, persistent abdominal pain immediately). Dual-pathway medications carry the same boxed warning regarding thyroid C-cell tumors and are not appropriate with a personal or family history of medullary thyroid carcinoma or MEN2.

What KAYU prescribes

KAYU prescribes brand-name, FDA-approved dual-pathway injectables dispensed by licensed pharmacies at their published cash-pay price. We do not prescribe compounded versions of these medications. Your provider tells you exactly which product is being prescribed and what it costs before you start.

The KAYU approach

Dual-pathway protocols at KAYU start with the same full metabolic panel as any incretin-based weight-loss protocol, because the medication is the easy decision and the underlying metabolic picture is the important one. Your provider builds the protocol with a muscle-preservation plan and a defined maintenance and off-ramp strategy, not a prescription and a wish of luck.